Abstract: Provided is a cell proliferation inhibitor comprising a compound of the formula (1) or a pharmacologically acceptable salt thereof: wherein J1 and J2 each represent CH or N, with the proviso that J1 and J2 are not simultaneously CH; r represents 0 to 4; each R101 is the same or different when r is 2 or more, and R101 represents a C1-6 alkyl group optionally substituted with a halogen atom or the like; s represents 0 to 5; each R102 is the same or different when s is 2 or more, and R102 represents a halogen atom or the like; R103 represents a hydrogen atom, a C1-6 alkyl group, a C3-6 cycloalkyl group, or a C3-6 cycloalkyl C1-6 alkyl group; and R101 and R103 are optionally linked together to form a five- to seven-membered ring hetero ring when R101 is present at the 8-position.

Abstract: Using the cobblestone area (CA) formation inhibitory activity of human leukemic stem cell-like cells as an indicator, a fraction having the activity has been extracted from the fat-soluble fraction of Porifera, then, a compound having the activity has been isolated and purified from the aforementioned fraction, and then, the structure thereof has been determined, so that a Stelliferin compound comprising a novel compound has been identified. Moreover, it has been found that the isolated and purified Stelliferin compound significantly suppresses the niche formation of leukemic stem cell-like cells derived from human chronic myelogenous leukemia (CML) having resistance to existing antitumor agents and enhances the effects of antitumor agents on the cells.

Abstract: Provided is a novel technique for reducing damage and death of microbial cells through a method for producing highly viable dried microbial cells, the method being characterized by subjecting dried microbial cells to an alternating temperature treatment.

Abstract: The present invention relates to a method for simply diagnosing the progress of disease condition of a Parkinson's disease patient. Provided are a method for determining Parkinson's disease using the number of one or more intestinal bacteria selected from the group consisting of Bifidobacterium, Bacteroides fragilis group, Lactobacillus brevis, and Lactobacillus plantarum subgroup and/or the total number of intestinal bacteria as a marker, and a method for determining Parkinson's disease using the blood LPS level and/or the blood LBP level of a Parkinson's disease patient as an indicator.

Abstract: Provided is a method for improving the production amount of a tri- or higher galactooligosaccharide and the reaction rate by a method for producing a galactooligosaccharide characterized by allowing ?-galactosidase to react with a substrate in the presence of 5 to 60 mM sodium ions and 0.5 to 8 mM magnesium ions.

Abstract: An object is to provide a method for producing dried microbial cells with a high viable cell survival rate after long-term storage at a high temperature. A method for producing dried microbial cells that achieves the above-mentioned object is characterized in that microbial cells are suspended in a dispersion medium containing a protective agent, an antioxidant, and a chelating agent, followed by drying.

Abstract: Provided is a method for preparing a specimen for extensively analyzing a resident skin bacterium and/or a substance present in the stratum corneum, such as a protein or a lipid, or observing the shape of the stratum corneum. A method for preparing a specimen for analyzing a resident skin bacterium and/or a substance present in the stratum corneum or observing the shape of the stratum, comprising applying a solution containing a polyvinyl alcohol polymer to the skin so as to form a thin-film and peeling and collecting the formed thin-film.

Abstract: Provided is a technique for enabling a liquid of microbial cells having an enzymatic activity to be easily stored and used. The technique is a method for killing a microorganism while maintaining the enzyme titer of a microbial cell liquid, characterized by including adjusting the pH of a liquid of microbial cells having an enzymatic activity, and then performing a heating treatment of the liquid, and also the technique is a method for killing a microorganism while maintaining the enzyme titer of a microbial cell liquid, characterized by including adding a carbohydrate to a liquid of microbial cells having an enzymatic activity, and then performing a heating treatment of the liquid.

Abstract: Disclosed herein is a method for determining whether a test subject has equol-producing ability or not. The method involves measuring equol-producing ability of a test subject, wherein an equol converting enzyme gene derived from enteric bacteria of the test subject is detected using three types of primer sets described herein as the primer sets a) to c).

Abstract: The object of the present invention is to provide a method of culturing lactic acid bacteria to obtain a lactic acid bacteria culture in which the number of lactic acid bacteria can be stably maintained, and to obtain food and drink products comprising a lactic acid bacteria culture excellent in product stability. In order to accomplish the object, the present invention provides a method of culturing lactic acid bacteria comprising inoculating lactic acid bacteria to a medium comprising a milk ingredient having a free phosphoric acid concentration of less than 0.25 wt %, and a phosphate, and food and drink products comprising the lactic acid bacteria culture obtained by this culturing method.

Abstract: Provided is a novel marker for determining sensitivity to an anti-cancer agent. The marker for determining sensitivity to an anti-cancer agent, the anti-cancer agent including oxaliplatin or a salt thereof, fluorouracil or a salt thereof, and levofolinate or a salt thereof, the marker comprising one or more substances selected from the group consisting of 2DG6P, 2MSE, CSSG, DOPM, GSSG, I4A, P2CB, 1-methyl-2-pyrrolidone, ASP, benzamide, glucaric acid, GL6P, Gly-Gly, HYPT and HYPX.

Abstract: Provided is a culture product having a mild rose aroma and suitable for imparting the rose aroma to a cosmetic product, a food or a drink, a pharmaceutical product, and the like. A culture product, which is obtained by fermenting a lactic acid bacterium culture product in a medium containing a milk component with Kluyveromyces marxianus, and comprises isoamyl alcohol in an amount of 0.3 to 5 parts by mass with respect to 1 part by mass of phenylethyl acetate.

Abstract: Provided are: an oligosaccharide powder having high working properties, the oligosaccharide powder being characterized by containing a dextrin having a dextrose equivalent of 10 to 18 and an oligosaccharide; and a method for manufacturing the same.

Abstract: Provided is a pharmaceutical composition suitable for administration of anticancer drugs into lymph nodes by means of lymphatic drug delivery systems. A pharmaceutical composition for therapeutic or prophylactic treatment of cancer to be administered into lymph nodes, comprising at least one anticancer drug selected from the group consisting of antimetabolites and anticancer plant alkaloids as an active ingredient.

Abstract: Provided is antitumor therapy using oncolytic viruses which exhibits an excellent antitumor effect and has reduced adverse effects. An antitumor agent, comprising a combination of an oncolytic virus and an anticancer agent selected from the group consisting of oxaliplatin, an anticancer plant alkaloid, and an antimetabolite.

Abstract: Provided is a method for efficiently manufacturing high-purity peripheral nerve cells from undifferentiated cells. The method for manufacturing peripheral nerve cells from undifferentiated cells having an ability to differentiate into peripheral nerve cells includes the following steps (a) and (b): (a) culturing undifferentiated cells having an ability to differentiate into peripheral nerve cells to induce differentiation into neural progenitor cells without detaching a grown colony from a culture vessel; and (b) detaching the neural progenitor cells produced in the step (a) from the culture vessel, then seeding the cells at a seeding density of 2×105 to 6×105 cells/cm2 to a culture vessel, and culturing the cells for 14 to 42 days.

Abstract: A culture product comprising a large quantity of ethyl benzoate and has a more complex and fresher fruity aroma than a chemically synthesized product. The culture product is obtained by culturing a microorganism belonging to the genus Wickerhamomyces in a milk component-containing culture medium.

Abstract: To provide an anti-cancer agent sensitivity determination marker, which marker can determine whether or not the patient has a therapeutic response to the anti-cancer agent, and novel cancer therapeutic means employing the marker. The anti-cancer agent sensitivity determination marker, the anti-cancer agent including oxaliplatin or a salt thereof and fluorouracil or a salt thereof, contains one or more substances selected from among an amino-acid-metabolism-related substance, a nucleic-acid-metabolism-related substance, a substance in the pentose phosphate pathway, a substance in the glycolytic pathway, a substance in the TCA cycle, a polyamine-metabolism-related substance, 7,8-dihydrobiopterin, 6-phosphogluconic acid, butyric acid, triethanolamine, 1-methylnicotinamide, NADH, NAD+, and a substance involved in the metabolism of any of these substances.

Abstract: An object of the present invention is to develop a means capable of maintaining the enzymatic activity of a microorganism even in a dry state. Provided is a method for producing a dry microbial cell powder maintaining an enzyme titer, characterized by comprising adding a carbohydrate to a liquid of microbial cells having an enzymatic activity and then drying the liquid. Also provided is a dry microbial cell powder obtained by the method.

Abstract: A pentosidine production inhibitor including a lactic acid bacterium fermentation product as an active ingredient, which has a stronger action and a high safety as a component having an action of inhibiting production of pentosidine.